Literature DB >> 15181721

[Sepsis, a complicated syndrome with major medical and social consequences].

J Bakker1, M Levi, B A van Hout, A van Gestel.   

Abstract

Severe sepsis is a life-threatening complication of infection. Due to associated organ-failure treatment in an Intensive Care Unit is usually indicated. Since sepsis is defined by the combination and progression of clinical events, correct definitions are essential to enable good comparison between study results and determination of suitable treatment. Severe sepsis is associated with a mortality of 20-60% and decreases the health-related quality of life in survivors. It is estimated that annually in the Netherlands 9000 patients are admitted to an Intensive Care Unit with severe sepsis. Direct medical costs of severe sepsis are estimated at [symbol: see text] 19,500 per patient. Costs correlate strongly with the length of stay. Annually Euro dollar 168,6 million is spent on severe sepsis, which represents 0.5% of all health-care costs and 1.7% of the annual hospital budget in the Netherlands.

Entities:  

Mesh:

Year:  2004        PMID: 15181721

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  3 in total

1.  Non-invasive monitoring of mitochondrial oxygenation and respiration in critical illness using a novel technique.

Authors:  Floor A Harms; Sander I A Bodmer; Nicolaas J H Raat; Egbert G Mik
Journal:  Crit Care       Date:  2015-09-22       Impact factor: 9.097

2.  Risk stratification by abbMEDS and CURB-65 in relation to treatment and clinical disposition of the septic patient at the emergency department: a cohort study.

Authors:  Asselina A Roest; Jan Tegtmeier; Joris J Heyligen; Jeanette Duijst; Andrea Peeters; Hella F Borggreve; Astrid M L Oude Lashof; Coen D A Stehouwer; Patricia M Stassen
Journal:  BMC Emerg Med       Date:  2015-10-13

3.  Management of sepsis in out-of-hours primary care: a retrospective study of patients admitted to the intensive care unit.

Authors:  Feike J Loots; Marleen Smits; Carlijn van Steensel; Paul Giesen; Rogier M Hopstaken; Arthur R H van Zanten
Journal:  BMJ Open       Date:  2018-09-17       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.